|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
over 90 countries
intramuscular injection
|
|
gptkbp:adverseEvents
|
rare blood clotting events
|
|
gptkbp:alsoKnownAs
|
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
|
|
gptkbp:approvedBy
|
gptkb:African_Union
gptkb:Bangladesh
gptkb:India
gptkb:Nepal
gptkb:Sri_Lanka
January 2021
|
|
gptkbp:associatedWith
|
gptkb:Vaxzevria
gptkb:AZD1222
|
|
gptkbp:basedOn
|
gptkb:ChAdOx1_nCoV-19_platform
|
|
gptkbp:category
|
gptkb:COVID-19_pandemic_in_India
gptkb:AstraZeneca_COVID-19_vaccine
Serum Institute of India products
essential medicine (India)
|
|
gptkbp:clinicalTrialPhase
|
Phase 3 trials in UK, Brazil, South Africa
|
|
gptkbp:contains
|
replication-deficient chimpanzee adenovirus vector
SARS-CoV-2 spike protein genetic material
|
|
gptkbp:countryOfOrigin
|
gptkb:India
gptkb:United_Kingdom
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:distribution
|
global
|
|
gptkbp:doseSchedule
|
two doses
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
about 70%
|
|
gptkbp:emergencyServices
|
gptkb:World_Health_Organization
many countries
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Covishield
|
|
gptkbp:intervalBetweenDoses
|
4 to 12 weeks
|
|
gptkbp:manufacturer
|
gptkb:Serum_Institute_of_India
|
|
gptkbp:notRecommendedFor
|
children under 18 years (initially)
people with severe allergic reaction to vaccine ingredients
|
|
gptkbp:pricePerDose
|
varies by country and procurement
|
|
gptkbp:recommendation
|
adults
|
|
gptkbp:regulates
|
gptkb:Drugs_Controller_General_of_India
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
chills
injection site pain
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:usedIn
|
gptkb:COVAX_program
|
|
gptkbp:WHOEmergencyUseListing
|
February 2021
|
|
gptkbp:bfsParent
|
gptkb:COVID-19
|
|
gptkbp:bfsLayer
|
4
|